Scandinavian journal of immunology

How COVID-19 mRNA Vaccines May Make Tumors More Responsive to Immune Therapy Blocking PD-1/PD-L1

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

SARS-CoV-2 mRNA vaccines may reprogram the tumor microenvironment.

  • These vaccines are associated with enhanced efficacy of PD-1/PD-L1 blockade.
  • The findings suggest potential applications for mRNA technology in cancer treatment.
  • Reprogramming of the tumor microenvironment could lead to improved immune responses.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '25
COVID-19 mRNA vaccines may help tumors respond better to immune checkpoint therapy
🏆 top 0.1% journal
cited by 49 papers
journal article
Nov '21
PD-1 blockade may reduce immune problems after COVID-19 and boost the immune response against the virus
top 5% journal
cited by 75 papers
research support, non-u.s. gov't
Jan '22
Immune responses six months after COVID-19 vaccination in cancer patients receiving immune checkpoint therapy with or without chemotherapy
top 2% journal
cited by 16 papers
research support, non-u.s. gov't
Nov '25
Blocking PD-1/PD-L1 and IL-33/ST2 pathways as a promising breast cancer immunotherapy
top 20% journal
cited by 4 papers
journal article
Dec '25
A peptide from the COVID-19 spike protein boosts immune responses and improves anti-PD-L1 cancer therapy against melanoma
top 10% journal
cited by 1 paper
journal article
Sep '24
Types and Locations of Cells That Respond to PD-1/PD-L1 Blockade
top 2% journal
cited by 8 papers
research support, non-u.s. gov't
Oct '25
PD-L1 targeting bispecific T cell engager kills PD-L1 tumor cells while blocking PD-1 and changing the tumor immune environment
top 2% journal
cited by 1 paper
journal article
Nov '25
Improving PD-1/PD-L1 cancer therapy by targeting sugar-binding proteins to boost immune response
top 5% journal
journal article
Nov '21
Detailed Mapping of Antibody Targets on the COVID-19 Vaccine Spike Protein
top 20% journal
cited by 27 papers
research support, non-u.s. gov't
Mar '21
Immunotherapy and its early signs in the immune system
top 20% journal
cited by 3 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the mrna technology brief

issue #49
A single antibody-coated nanoparticle edits blood stem cells inside living mice
6 days ago7 studies
issue #48
A new RNA polymerase makes self-amplifying vaccine production 9x easier
1 week ago7 studies
issue #47
Engineers used AI to design a self-destruct switch that kills virus-infected cells on command
2 weeks ago7 studies
issue #46
A simple ligand swap redirected liver-targeting nanoparticles to the lungs with 200-fold more mRNA delivery
3 weeks ago7 studies
issue #45
A $1 device delivers naked mRNA vaccines as effectively as lipid nanoparticles in mice and human skin
4 weeks ago7 studies
issue #44
Light-activated lipid nanoparticles spin their way out of cellular traps to boost cancer vaccine results
5 weeks ago7 studies
issue #43
A common antibiotic switches self-amplifying RNA vaccines on and off — with 10x range between states
6 weeks ago7 studies
issue #42
A single LNP dose achieved 49% liver gene editing in mice — without viral vectors
7 weeks ago7 studies
issue #41
Buffer choice affects mRNA vaccine performance by 40% after freeze-thaw cycles
8 weeks ago7 studies
issue #40
mRNA vaccine boosted cancer immunotherapy survival rates by 70-80% in mice
9 weeks ago7 studies
explore the archive
See more issues from the mrna technology brief